Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 10/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523005 | 0.83 | THRB (0.42) | THRBTGFBR1CSNK1DCSNK1EMAPK14 | |
| SCHEMBL14844873 | 0.80 | THRB (0.53) | THRBTGFBR1CSNK1DCSNK1EMAPK14 | |
| SCHEMBL18115090 | 0.79 | CSNK1D (0.48) | THRBTGFBR1CSNK1DCSNK1EMAPK14 | |
| SCHEMBL14844957 | 0.79 | TGFBR1 (0.54) | THRBTGFBR1CSNK1EMAPK14CYP11B1 | |
| SCHEMBL14844882 | 0.78 | THRB (0.52) | THRBTGFBR1CSNK1DCSNK1EMAPK14 | |
| SCHEMBL14844860 | 0.76 | THRB (0.43) | THRBTGFBR1CSNK1DCSNK1ECYP11B1 | |
| SCHEMBL17373680 | 0.75 | THRB (0.49) | THRBTGFBR1CSNK1DCSNK1EMAPK14 | |
| SCHEMBL24348532 | 0.75 | TGFBR1 (0.56) | THRBTGFBR1CSNK1DCSNK1EMAPK14 | |
| SCHEMBL29049906 | 0.75 | TGFBR1 (0.55) | THRBTGFBR1CSNK1DMAPK14 | |
| SCHEMBL18115007 | 0.74 | THRB (0.51) | THRBTGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230123591-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11466018-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3277673-B1 | TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210130361-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-10822337-B2 | TGF-β inhibitorC | RIGEL PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | THRB 102/4885TGFBR1 1/4885CSNK1D 829/4885 |
| US-10822337-B2 | TGF-β inhibitorC | TGFBR1, TGFBR2, TGFB1 | THRB 193/4885TGFBR1 1/4885CSNK1D 799/4885 |
| US-11466018-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | THRB 102/4885TGFBR1 1/4885CSNK1D 829/4885 |
| US-20210130361-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | THRB 86/4885TGFBR1 1/4885CSNK1D 746/4885 |
| US-20180086764-A1 | TGF-ß Inhibitors | TGFBR1, TGFBR2, TGFB1 | THRB 86/4885TGFBR1 1/4885CSNK1D 746/4885 |
| US-20230123591-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | THRB 86/4885TGFBR1 1/4885CSNK1D 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.